Researchers in npj Parkinson’s Disease reported that a peripheral diagnostic panel can help decode clinical masking in SAA-positive Parkinson’s disease, aiming to address diagnostic ambiguity even after lab tests identify disease-associated proteins. The study examines how Parkinson’s can present biologically before it becomes clinically obvious. The paper by Zuo, Li, Chen and colleagues focuses on what they describe as “clinical masking,” where the expected clinical picture may not match the biomarker signal at the time of testing. The diagnostic panel is positioned as a tool to interpret these situations rather than relying on protein detection alone. For the biotech and diagnostics ecosystem, the work reinforces the need for multi-parameter approaches that combine biomarkers with clinical context, especially for early diagnosis, clinical trial enrichment, and progression studies. The practical upshot is that diagnostic platforms may need to account for heterogeneity in phenotype expression timing, even when molecular markers are present.